Advertisement

A rapid review of patient-reported outcomes investigated in the context of advanced renal cell cancer or advanced hepatocellular cancer

Published:November 15, 2022DOI:https://doi.org/10.1016/j.ejon.2022.102241

      Highlights

      • We explored what PROs are commonly reported in advanced renal or liver cancer.
      • Quality of life and physical symptoms were the most frequently assessed PROs.
      • Whether selection of these PROs was patient-driven was not reported.
      • Clinicians must address the ‘right’ PROs for person-centred care to be enhanced.

      Abstract

      Background

      Patient-reported outcomes (PROs) are key indicators of health status and functioning, coming directly from the patient. Comprehensive monitoring of PROs enables implementation of person-centred care. Currently, the PROs that patients with advanced renal cell carcinoma (RCC) or hepatocellular carcinoma (HCC) consider of greatest importance remains unknown.

      Methods

      A rapid literature review was carried out to identify PROs commonly reported in clinical studies of patients with advanced RCC/HCC. We searched MEDLINE, CINAHL & PsycInfo for relevant peer-reviewed publications in the period from 2000 to 2021. Pre-specified selection criteria were applied to all retrieved records. Findings were integrated into a narrative synthesis.

      Results

      Eighty-one studies met our selection criteria and were retained. Most research was on advanced RCC (n = 64, 79%); 46 studies (57%) were drug trials. No qualitative research on PROs was found. Only twenty-six studies (32%) employed PROs as their primary endpoint. Most PROs concerned physical symptoms (45% RCC, 54% HCC) and emotional wellbeing (19% RCC, 16% HCC). The most common outcome measured was quality of life (65% of the total), followed by fatigue (62%) and pain (54%). Whether selection of these PROs was patient-driven was not reported.

      Conclusions

      A wide range of PROs were assessed. Deficits in PROs often cause patients to seek out help; however, which PROs matter the most to people with advanced RCC/HCC must be further clarified. Targeting, monitoring, and responding to the ‘right’ PROs can enhance provision of person-centred care in advanced RCC/HCC and augment the clinical efficacy of established and emerging targeted therapies.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Oncology Nursing
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bhavsar N.A.
        • Harrison M.R.
        • Hirsch B.R.
        • Creel P.
        • Wolf S.P.
        • Samsa G.P.
        • Abernethy A.P.
        • Simantov R.
        • Borham A.
        • George D.J.
        Design and rationale of the metastatic renal cell carcinoma (MaRCC) registry: a prospective academic and community-based study of patients with metastatic renal cell cancer.
        Cancer Invest. 2017; 35: 333-344https://doi.org/10.1080/07357907.2017.1289215
        • Butt Z.
        • Parikh N.D.
        • Beaumont J.L.
        • Rosenbloom S.K.
        • Syrjala K.L.
        • Abernethy A.P.
        • Benson A.B.
        • Cella D.
        Development and validation of a symptom index for advanced hepatobiliary and pancreatic cancers: the national comprehensive cancer Network functional assessment of cancer therapy (NCCN-FACT) hepatobiliary-pancreatic symptom index (NFHSI).
        Cancer. 2012; 118: 5997-6004https://doi.org/10.1002/cncr.27588
        • Capitanio U.
        • Bensalah K.
        • Bex A.
        • Boorjian S.A.
        • Bray F.
        • Coleman J.
        • Gore J.L.
        • Sun M.
        • Wood C.
        • Russo P.
        Epidemiology of renal cell carcinoma.
        Eur. Urol. 2019; 75: 74-84https://doi.org/10.1016/j.eururo.2018.08.036
        • Cella D.
        Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma.
        Oncol. 2011; 16: 23-31https://doi.org/10.1634/theoncologist.2011-S2-23
        • Cella D.
        • Hahn E.A.
        • Jensen S.E.
        • Butt Z.
        • Nowinski C.J.
        • Rothrock N.
        • Lohr K.N.
        Types of Patient-Reported Outcomes.
        2015
        • Cella D.
        • Motzer R.J.
        • Rini B.I.
        • Cappelleri J.C.
        • Ramaswamy K.
        • Hariharan S.
        • Arondekar B.
        • Bushmakin A.G.
        Important group differences on the functional assessment of cancer therapy-kidney symptom index disease-related symptoms in patients with metastatic renal cell carcinoma.
        Value Health. 2018; 21: 1413-1418https://doi.org/10.1016/j.jval.2018.04.1371
        • Cella D.
        • Rosenbloom S.K.
        • Beaumont J.L.
        • Yount S.E.
        • Paul D.
        • Hampton D.
        • Abernethy A.P.
        • Jacobsen P.B.
        • Syrjala K.
        • Roenn J.H. Von
        Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer.
        J. Natl. Compr. Cancer Netw. 2011; 9: 268
        • Cella D.
        • Yount S.
        • Du H.
        • Dhanda R.
        • Gondek K.
        • Langefeld K.
        • George J.
        • Bro W.P.
        • Kelly C.
        • Bukowski R.
        Development and validation of the functional assessment of cancer therapy-kidney symptom index (FKSI).
        J. Support Oncol. 2006; 4: 191-199
        • Chaar E.A.
        • Hallit S.
        • Hajj A.
        • Aaraj R.
        • Kattan J.
        • Jabbour H.
        • Khabbaz L.R.
        Evaluating the impact of spirituality on the quality of life, anxiety, and depression among patients with cancer: an observational transversal study.
        Support. Care Cancer. 2018; 268 (2018): 2581-2590https://doi.org/10.1007/S00520-018-4089-1
        • Dawber R.
        • Armour K.
        • Ferry P.
        • Mukherjee B.
        • Carter C.
        • Meystre C.
        Comparison of informal caregiver and named nurse assessment of symptoms in elderly patients dying in hospital using the palliative outcome scale.
        BMJ Support. Palliat. Care. 2019; 9: 175-182https://doi.org/10.1136/BMJSPCARE-2015-000850
        • Denouel A.
        • Heutte N.
        • Escudier B.
        • Kurtz J.-E.
        • Dos Santos M.
        • Longato N.
        • Desrues L.
        • Dauchy S.
        • Lange M.
        • Sevin E.
        • Rieux C.
        • Clarisse B.
        • Castel H.
        • Noal S.
        • Joly F.
        Sexual disorders of patients with metastatic renal cell carcinoma (mRCC) treated with antiangiogenic therapies.
        Clin. Genitourin. Cancer. 2018; 16: 369https://doi.org/10.1016/j.clgc.2018.05.013
        • Drury A.
        • Payne S.
        • Brady A.M.
        Prevalence vs impact: a mixed methods study of survivorship issues in colorectal cancer.
        Qual. Life Res. 2022; 31: 1117-1134
        • Escudier B.
        • Grünwald V.
        • Gillessen S.
        • Horwich A.
        • Porta C.
        • Schmidinger M.
        • Rioux-Leclercq N.
        • Bex A.
        • Khoo V.
        Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
        Ann. Oncol. 2019; (in press)https://doi.org/10.1093/annonc/mdz056
        • Escudier B.
        • Porta C.
        • Schmidinger M.
        • Rioux-Leclercq N.
        • Bex A.
        • Khoo V.
        • Grünwald V.
        • Gillessen S.
        • Horwich A.
        Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
        Ann. Oncol. 2019; 30: 706-720https://doi.org/10.1093/annonc/mdz056
        • Firkins J.L.
        • Tarter R.
        • Driessnack M.
        • Hansen L.
        A closer look at quality of life in the hepatocellular carcinoma literature.
        Qual. Life Res. 2021; https://doi.org/10.1007/s11136-021-02789-2
        • Flannery M.A.
        • Culakova E.
        • Canin B.E.
        • Peppone L.
        • Ramsdale E.
        • Mohile S.G.
        Understanding Treatment Tolerability in Older Adults with Cancer.
        2021: 2150-2163https://doi.org/10.1200/JCO.21.00195
        • Foster C.
        • Calman L.
        • Richardson A.
        • Pimperton H.
        • Nash R.
        Improving the lives of people living with and beyond cancer: generating the evidence needed to inform policy and practice.
        J. Cancer Policy. 2018; 15: 92-95https://doi.org/10.1016/j.jcpo.2018.02.004
        • Gao X.
        • McDermott D.F.
        • Michaelson M.D.
        Enhancing antitumor immunity with antiangiogenic therapy: a clinical model in renal cell carcinoma?.
        Oncol. 2019; 24: 725-727https://doi.org/10.1634/theoncologist.2019-0165
        • Ghouri Y.
        • Mian I.
        • Rowe J.
        Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis.
        J. Carcinog. 2017; 16https://doi.org/10.4103/jcar.jcar_9_16
        • Goebell P.J.
        • Müller L.
        • Hurtz H.-J.
        • Koska M.
        • Busies S.
        • Marschner N.
        A cross-sectional investigation of fatigue, mucositis, hand-foot syndrome and dysgeusia in advanced renal cell carcinoma treatment: final results from the FAMOUS study.
        Clin. Genitourin. Cancer. 2016; 14: 63-68https://doi.org/10.1016/j.clgc.2015.09.004
        • Goebell P.J.
        • Münch A.
        • Müller L.
        • Hurtz H.
        • Koska M.
        • Busies S.
        • Marschner N.
        A cross-sectional investigation of fatigue in advanced renal cell carcinoma treatment: results from the FAMOUS study.
        Urol. Oncol. 2014; 32: 362-370https://doi.org/10.1016/j.urolonc.2013.09.009
        • Greenhalgh J.
        • Gooding K.
        • Gibbons E.
        • Dalkin S.
        • Wright J.
        • Valderas J.
        • Black N.
        How do patient reported outcome measures (PROMs) support clinician-patient communication and patient care? A realist synthesis.
        J. Patient-Reported Outcomes. 2018; 21 (2018): 1-28https://doi.org/10.1186/S41687-018-0061-6
        • Haanen J.
        • Carbonnel F.
        • Robert C.
        • Kerr K.
        • Peters S.
        • Larkin J.
        • Jordan K.
        Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
        Ann. Oncol. 2017; 28: i119-i142
        • Hansen L.
        • Dieckmann N.F.
        • Kolbeck K.J.
        • Naugler W.E.
        • Chang M.F.
        Symptom distress in patients with hepatocellular carcinoma toward the end of life.
        Oncol. Nurs. Forum. 2017; 44: 665-673https://doi.org/10.1188/17.ONF.665-673
        • Harding G.
        • Cella D.
        • Robinson D.
        • Mahadevia P.J.
        • Clark J.
        • Revicki D.A.
        Symptom burden among patients with Renal cell carcinoma (RCC): content for a symptom index.
        Health Qual. Life Outcome. 2007; 5: 34https://doi.org/10.1186/1477-7525-5-34
        • Hato T.
        • Zhu A.X.
        • Duda D.G.
        Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma.
        Immunotherapy. 2016; 8: 299-313https://doi.org/10.2217/imt.15.126
        • Higgins J.
        • Thomas J.
        • Chandler J.
        • Cumpston M.
        • Li T.
        • Page M.
        • Welch V.
        Cochrane handbook for systematic reviews of interventions | cochrane training.
        ([WWW Document]. Handbook. URL) (accessed 08.06.2021)
        • Howell D.
        • Molloy S.
        • Wilkinson K.
        • Green E.
        • Orchard K.
        • Wang K.
        • Liberty J.
        Patient-reported outcomes in routine cancer clinical practice: a scoping review of use, impact on health outcomes, and implementation factors.
        Ann. Oncol. 2015; https://doi.org/10.1093/annonc/mdv181
        • International Agency for Research on Cancer
        GLOBOCAN: Estimated Number of New Cases in 2020.
        2020 (worldwide, both sexes, all ages [WWW Document]. WHO. URL) (accessed 01.31.2021)
        • Kang D.
        • Shim S.
        • Cho J.
        • Lim H.
        Systematic review of studies assessing the health-related quality of life of hepatocellular carcinoma patients from 2009 to 2018.
        Korean J. Radiol. 2020; 21: 633-646https://doi.org/10.3348/KJR.2019.0808
        • Kelly D.
        • Fernández-Ortega P.
        • Arjona E.
        • Daniele B.
        The role of nursing in the management of patients with renal and hepatic cancers: a systematic literature review.
        Eur. J. Oncol. Nurs. 2021; 55https://doi.org/10.1016/J.EJON.2021.102043
        • Kingsley C.
        • Patel S.
        Patient-reported outcome measures and patient-reported experience measures.
        BJA Educ. 2017; 17: 137-144https://doi.org/10.1093/bjaed/mkw060
        • Kyte D.
        • Duffy H.
        • Fletcher B.
        • Gheorghe A.
        • Mercieca-Bebber R.
        • King M.
        • Draper H.
        • Ives J.
        • Brundage M.
        • Blazeby J.
        • Calvert M.
        Systematic evaluation of the patient-reported outcome (PRO) content of clinical trial protocols.
        PLoS One. 2014; 9e110229https://doi.org/10.1371/JOURNAL.PONE.0110229
        • Maiko S.
        • Johns S.A.
        • Helft P.R.
        • Slaven J.E.
        • Cottingham A.H.
        • Torke A.M.
        Spiritual experiences of adults with advanced cancer in outpatient clinical settings.
        J. Pain Symptom Manag. 2019; 57 (e1): 576-586https://doi.org/10.1016/J.JPAINSYMMAN.2018.11.026
        • Mercieca-Bebber R.
        • King M.T.
        • Calvert M.J.
        • Stockler M.R.
        • Friedlander M.
        The importance of patient-reported outcomes in clinical trials and strategies for future optimization.
        Patient Relat. Outcome Meas. 2018; 9: 353https://doi.org/10.2147/PROM.S156279
        • Moher D.
        • Liberati A.
        • Tetzlaff J.
        • Altman D.G.
        Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
        BMJ. 2009; https://doi.org/10.1136/bmj.b2535
        • Moldawer N.P.
        • Wood L.S.
        The critical role of the Oncology nurse as a partner in the management of patients with advanced kidney cancer: toxicity management, symptom control, and palliative care.
        Cancer J. 2020; 26: 460-463https://doi.org/10.1097/PPO.0000000000000476
        • Nichol K.
        • Stacey D.
        • Kuziemsky C.
        • Gifford W.
        Cancer symptom management in the home: a scoping review.
        Can. Oncol. Nurs. J. 2016; 26: 4-10
        • Patient-reported outcomes (PROs) assessment - EUPATI Toolbox [WWW Document], n.d
        (URL) (accessed 07.19.2021)
        • Powles T.
        • Albiges L.
        • Bex A.
        • Grünwald V.
        • Porta C.
        • Procopio G.
        • Schmidinger M.
        • Suárez C.
        • de Velasco G.
        ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma.
        Ann. Oncol. 2021; 32: 1511-1519https://doi.org/10.1016/J.ANNONC.2021.09.014
        • Puzanov I.
        • Diab A.
        • Abdallah K.
        • Bingham C.O.
        • Brogdon C.
        • Dadu R.
        • Hamad L.
        • Kim S.
        • Lacouture M.E.
        • LeBoeuf N.R.
        • Lenihan D.
        • Onofrei C.
        • Shannon V.
        • Sharma R.
        • Silk A.W.
        • Skondra D.
        • Suarez-Almazor M.E.
        • Wang Y.
        • Wiley K.
        • Kaufman H.L.
        • Ernstoff M.S.
        • Anderson J.
        • Lehman K.
        • Reshef D.
        • Saylors A.
        • Turner M.
        • Waxman I.
        • Arrindell D.
        • Andrews S.
        • Ballesteros J.
        • Boyer J.
        • Cotarla I.
        • Dawson M.
        • Goswami T.
        • Hayreh V.
        • Holmes W.
        • Rasheed Z.
        • Sarkeshik M.
        • Schreiber J.
        • Shafer-Weaver K.
        • Chen D.
        • Ley-Acosta S.
        • Chonzi D.
        • Go W.
        • Cunha R.
        • Gulley J.L.
        • Wood L.
        • Davies M.
        • Dicker A.
        • Eifler L.
        • Gregory N.
        • Ferguson A.
        • Ferlini C.
        • Frankel S.
        • Gochett C.
        • Goldberg J.
        • Patel K.
        • Wariabharaj D.
        • Goncalves P.
        • Helie N.
        • Hsu J.Y.
        • Ibrahim R.
        • Larocca C.
        • Lambotte O.
        • Luke J.
        • McClure J.
        • Michelon E.
        • Nakamura M.
        • Piperdi B.
        • Riemer J.
        • Robert C.
        • Sharfman W.
        • Sharon E.
        • Sherry R.
        • Simonson C.
        • Thomas C.
        • Trehu E.
        • Thompson J.A.
        • Tresnan D.
        • Zhang L.
        • Zheng P.
        Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group.
        J. Immunother. Cancer. 2017; 5: 95https://doi.org/10.1186/s40425-017-0300-z
        • Rapoport B.L.
        • Eeden R.
        • Sibaud V.
        • Epstein J.B.
        • Klastersky J.
        • Aapro M.
        • Moodley D.
        • Rapoport B.L.
        • van Eeden R.
        • Epstein J.B.
        Supportive care for patients undergoing immunotherapy.
        Support. Care Cancer. 2017; 25: 3017-3030https://doi.org/10.1007/s00520-017-3802-9
        • Rothrock N.E.
        • Jensen S.E.
        • Beaumont J.L.
        • Abernethy A.P.
        • Jacobsen P.B.
        • Syrjala K.
        • Cella D.
        Development and initial validation of the NCCN/FACT symptom index for advanced kidney cancer.
        Value Health. 2013; 16: 789-796https://doi.org/10.1016/J.JVAL.2013.04.015
        • Toumi M.
        • Jarosławski S.
        • Chouhaid C.
        • Fallissard B.
        • Auquier P.
        Patient-reported outcomes in Oncology, beyond randomized controlled trials.
        Recent Results Cancer Res. 2019; 213: 57-65https://doi.org/10.1007/978-3-030-01207-6_5
        • Tzelepis F.
        • Sanson-Fisher R.W.
        • Zucca A.C.
        • Fradgley E.A.
        Measuring the quality of patient-centered care: why patient-reported measures are critical to reliable assessment. Patient Prefer.
        Adherence. 2015; 9 (2015): 831-835https://doi.org/10.2147/PPA.S81975
        • Ullgren H.
        • Tsitsi T.
        • Papastavrou E.
        • Charalambous A.
        How family caregivers of cancer patients manage symptoms at home: a systematic review.
        Int. J. Nurs. Stud. 2018; 85: 68-79https://doi.org/10.1016/j.ijnurstu.2018.05.004
        • Vogel A.
        • Cervantes A.
        • Chau I.
        • Daniele B.
        • Llovet J.
        • Meyer T.
        • Nault J.C.
        • Neumann U.
        • Ricke J.
        • Sangro B.
        • Schirmacher P.
        • Verslype C.
        • Zech C.J.
        • Arnold D.
        • Martinelli E.
        Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
        Ann. Oncol. 2018; 29: iv238-iv255https://doi.org/10.1093/annonc/mdy308
        • Vogel A.
        • Martinelli E.
        • Cervantes A.
        • Chau I.
        • Daniele B.
        • Llovet J.M.
        • Meyer T.
        • Nault J.C.
        • Neumann U.
        • Ricke J.
        • Sangro B.
        • Schirmacher P.
        • Verslype C.
        • Zech C.J.
        • Arnold D.
        Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines.
        Ann. Oncol. 2021; 32: 801-805https://doi.org/10.1016/J.ANNONC.2021.02.014
        • Zhou K.
        • Fountzilas C.
        Outcomes and quality of life of systemic therapy in advanced hepatocellular carcinoma.
        Cancers. 2019; https://doi.org/10.3390/cancers11060861